Interim

[키워드] 1:1 AAK1 absence activator Acute respiratory failure Administered administration Adverse adverse events affected alkaline phosphatase All participants allergy Alpha alpha error angina pectoris Antibiotics appearance ARDS Arm assigned AST/ALT Baricitinib baseline beta error Bilirubin Blinding Blood Breastfeeding can be used candidate Candidates capture Cardiac arrhythmia carried change clearance clinical clinical condition clinical suspicion clinical trials Coagulation Cohort Common Terminology Criteria Comorbidity Complete completion Compliance congestive heart failure control arm Controlled trial corticoid Corticosteroids COVID19 creatinine creatinine clearance CRP D-dimer Day Deep venous thrombosis description Deterioration Dexamethasone dimer discharge discretion disease dissemination diverticulitis dose dropout rate Duration of therapy ECMO Efficacy electronic case report form element eligibility criteria Enrollment evaluate exclusion criteria expected experimental arm extracorporeal membrane oxygenation febrile neutropenia ferritin followed by form fraction Gas exchange greater HBV HCV hemodynamic instability High-flow nasal cannula HIV HIV infection ICU immobilization immunological impossibility incidence include indication Infection infection with SARS-CoV-2 Inflammatory response interfere interferon Interim interim analysis interleukin interleukin 6 interstitial pneumonia Intervention intestinal perforation Invasive mechanical ventilation investigational agent investigator jak inhibitors Jak-STAT Laboratory laboratory parameter Laboratory parameters LDH less limit limits management mechanical ventilation medical history Medicine meet Methylprednisolone Mild ARDS Mortality multi organ failure nasal nasal cannula need for oxygen neutropenia neutrophil Neutrophils Non-invasive number objective on mechanical ventilation oncological patients onset of symptom open open label oral medication organ dysfunction Organ failure outcome oxygen oxygen support PaFi participant Participants Participation pathogen Pathogens pathway Patient patients performance status performed phase Phase 1 Phase 2 Phase I phosphatase platform Pneumonia poor prognosis positive Prednisone pregnancy test pregnant prejudice Prevent progression Prophylaxis Protein protein kinase protocol Psychiatric psychiatric illness Pulmonary embolism radiological randomisation randomised randomised controlled trial randomization Randomized Randomized controlled trial receive receptor recruitment REDCap REDcap platform reduce reduced Remdesivir removal report reported required respiratory Respiratory failure Respiratory function respiratory insufficiency respiratory tract Sample size SARS-CoV-2 SARS-CoV2 SARS-CoV2 infection Secondary objectives Sepsis severe adverse event severe adverse events severe pneumonia severe respiratory failure Spain Spanish Standard of care STAT status study enrollment Study protocol supplemental oxygen requirement supplemental oxygen requirements supplementary material Support surgical surgical intervention Symptom symptomatic Tablet Therapies therapy thromboembolic disease thrombosis Tocilizumab total bilirubin Toxicity Transcription transducer Treatment treatment period Trial unstable angina use of corticosteroid Venous thrombosis Version viral endocytosis website Withdrawal worsening
[DOI] 10.1186/s13063-021-05072-4 PMC 바로가기 [Article Type] Letter